For research use only. Not for therapeutic Use.
Velpatasvir（Cat No.:I001457）is a potent, selective inhibitor of the hepatitis C virus (HCV) NS5A protein, critical for the replication and assembly of the virus. It is used in combination therapies for the treatment of chronic HCV infection, including in patients with genotypes 1-6. By blocking the NS5A protein, Velpatasvir disrupts viral replication, leading to a reduction in viral load and improved outcomes. The drug has shown efficacy in both treatment-naive and treatment-experienced patients, with a favorable safety profile and minimal resistance development. Velpatasvir is a key agent in HCV eradication strategies.
| Catalog Number | I001457 |
| CAS Number | 1377049-84-7 |
| Synonyms | GS-5816 |
| Molecular Formula | C49H54N8O8 |
| Purity | 99% |
| Target | HCV |
| Solubility | DMSO |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | EC50：6 to 130 pM（GT1 to GT6) |
| IUPAC Name | methyl N-[(1R)-2-[(2S,4S)-2-[5-[6-[(2S,5S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-21-oxa-5,7-diazapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-1(13),2,4(8),5,9,11,14(19),15,17-nonaen-17-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate |
| InChI | InChI=1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1 |
| InChIKey | FHCUMDQMBHQXKK-CDIODLITSA-N |
| SMILES | C[C@H]1CC[C@H](N1C(=O)[C@H](C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)[C@@H]8C[C@@H](CN8C(=O)[C@@H](C9=CC=CC=C9)NC(=O)OC)COC |
| Reference | </br>1:Sofosbuvir-velpatasvir with ribavirin for 24 weeks in HCV patients previously treated with a direct-acting antiviral regimen. Gane EJ, Shiffman ML, Etzkorn K, Morelli G, Stedman C, Davis MN, Hinestrosa F, Dvory-Sobol H, Huang KC, Osinusi A, McNally J, Brainard DM, McHutchison JG, Thompson AJ, Sulkowski MS; GS-US-342-1553 Investigators..Hepatology. 2017 May 12. doi: 10.1002/hep.29256. [Epub ahead of print] PMID: 28498551 </br>2:Patient-Reported Outcomes in Patients Co-infected with HCV and HIV Treated with Sofosbuvir and Velpatasvir: The ASTRAL-5 Study. Younossi ZM, Stepanova M, Sulkowski M, Wyles D, Kottilil S, Hunt S.Liver Int. 2017 May 4. doi: 10.1111/liv.13462. [Epub ahead of print] PMID: 28470938 </br>3:Sofosbuvir and velpatasvir for the treatment of hepatitis C. Jackson WE, Everson GT.Expert Rev Gastroenterol Hepatol. 2017 Jun;11(6):501-505. doi: 10.1080/17474124.2017.1326817. Epub 2017 May 11. PMID: 28468532 </br>4:Sofosbuvir/velpatasvir fixed-dose combination for the treatment of chronic hepatitis C virus infection. Nehra V, Rizza SA, Temesgen Z.Drugs Today (Barc). 2017 Mar;53(3):177-189. doi: 10.1358/dot.2017.53.3.2604176. PMID: 28447075 </br>5:Sofosbuvir-velpatasvir for treating chronic hepatitis C. Cooper S, Umeweni N, Knight H, McVeigh G.Lancet Gastroenterol Hepatol. 2017 Mar;2(3):156-157. doi: 10.1016/S2468-1253(17)30009-2. Epub 2017 Jan 25. No abstract available. PMID: 28404128 </br>6:Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Younossi ZM, Stepanova M, Charlton M, Curry MP, O/’Leary JG, Brown RS, Hunt S.Lancet Gastroenterol Hepatol. 2016 Oct;1(2):122-132. doi: 10.1016/S2468-1253(16)30009-7. Epub 2016 Aug 3. PMID: 28404069 </br>7:Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir In Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. Jacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, Nahass RG, Borgia SM, Shafran SD, Workowski KA, Pearlman B, Hyland RH, Stamm LM, Svarovskaia E, Dvory-Sobol H, Zhu Y, Subramanian GM, Brainard DM, McHutchison JG, Bräu N, Berg T, Agarwal K, Bhandari BR, Davis M, Feld JJ, Dore GJ, Stedman CA, Thompson AJ, Asselah T, Roberts SK, Foster GR.Gastroenterology. 2017 Apr 5. pii: S0016-5085(17)35399-4. doi: 10.1053/j.gastro.2017.03.047. [Epub ahead of print] PMID: 28390869 </br>8:Sofosbuvir and Velpatasvir for the Treatment of HCV in Patients Coinfected with HIV-1: an Open-Label, Phase 3 Study. Wyles D, Bräu N, Kottilil S, Daar ES, Ruane P, Workowski K, Luetkemeyer A, Adeyemi O, Kim AY, Doehle B, Huang KC, Mogalian E, Osinusi A, McNally J, Brainard DM, McHutchison JG, Naggie S, Sulkowski M; ASTRAL-5 Investigators..Clin Infect Dis. 2017 Mar 29. doi: 10.1093/cid/cix260. [Epub ahead of print] PMID: 28369210 </br>9:Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure. Mir F, Kahveci AS, Ibdah JA, Tahan V.Drug Des Devel Ther. 2017 Feb 23;11:497-502. doi: 10.2147/DDDT.S130945. eCollection 2017. Review. PMID: 28260862 Free PMC Article</br>10:Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus. Lawitz E, Poordad F, Wells J, Hyland RH, Yang Y, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Landaverde C, Gutierrez J.Hepatology. 2017 Feb 21. doi: 10.1002/hep.29130. [Epub ahead of print] PMID: 28220512 |
